创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

闵祥燕, 曹宁, 严懿嘉, 陈志龙. 光动力新药帕利泊芬研究进展[J]. 药学进展, 2019, 43(3): 231-237.
引用本文: 闵祥燕, 曹宁, 严懿嘉, 陈志龙. 光动力新药帕利泊芬研究进展[J]. 药学进展, 2019, 43(3): 231-237.
MIN Xiangyan, CAO Ning, YAN Yijia, CHEN Zhilong. Research Progress in New Photodynamic Therapy with Padeliporfin[J]. Progress in Pharmaceutical Sciences, 2019, 43(3): 231-237.
Citation: MIN Xiangyan, CAO Ning, YAN Yijia, CHEN Zhilong. Research Progress in New Photodynamic Therapy with Padeliporfin[J]. Progress in Pharmaceutical Sciences, 2019, 43(3): 231-237.

光动力新药帕利泊芬研究进展

Research Progress in New Photodynamic Therapy with Padeliporfin

  • 摘要: 光动力疗法被广泛用于肿瘤临床治疗,应用前景广阔。近年来的研究表明帕利泊芬是一种水溶性良好的血管靶向光敏剂,静脉给药后可选择性地聚集于肿瘤细胞内,在光激活下释放大量活性氧,从而发挥抗肿瘤疗效。该药已在欧洲获准上市,用于前列腺癌的治疗。主要介绍帕利泊芬的发现历程与合成路线、药理作用以及临床研究进展,旨在为肿瘤光动力疗法的进一步探索提供参考。

     

    Abstract: Photodynamic therapy has been widely used in the treatment of tumors and has broad application prospect. Recent studies have shown that padeliporfin, a water-soluble vascular-targeting photosensitizer can selectively accumulate in tumor cells after intravenous administration and release a large amount of reactive oxygen species upon photoactivation, thereby exerting anti-tumor effect. This drug has been approved in Europe as a treatment for prostate cancer. This review mainly introduced the discovery process, synthetic route, pharmacological action and clinical research progress of padeliporfin, so as to provide reference for further exploration of tumor photodynamic therapy.

     

/

返回文章
返回